Charles Schwab Investment Management Inc. Raises Stake in uniQure (NASDAQ:QURE)

Charles Schwab Investment Management Inc. increased its position in uniQure (NASDAQ:QURE) by 6.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 277,275 shares of the biotechnology company’s stock after acquiring an additional 16,464 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.57% of uniQure worth $1,367,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of QURE. abrdn plc grew its holdings in shares of uniQure by 381.7% during the third quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after purchasing an additional 1,528,581 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in uniQure in the second quarter worth $815,000. Privium Fund Management B.V. increased its position in shares of uniQure by 16.3% during the third quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock valued at $3,672,000 after buying an additional 104,500 shares during the period. Algert Global LLC bought a new stake in shares of uniQure during the second quarter valued at approximately $176,000. Finally, Marshall Wace LLP bought a new position in shares of uniQure in the 2nd quarter worth about $175,000. 78.83% of the stock is owned by institutional investors.

uniQure Stock Performance

Shares of uniQure stock opened at $17.40 on Tuesday. uniQure has a 52 week low of $3.73 and a 52 week high of $17.71. The company has a market capitalization of $848.13 million, a PE ratio of -3.36 and a beta of 0.89. The stock’s fifty day moving average is $7.04 and its two-hundred day moving average is $6.38. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The business had revenue of $2.29 million during the quarter, compared to analyst estimates of $2.73 million. As a group, analysts expect that uniQure will post -3.82 earnings per share for the current year.

Insider Transactions at uniQure

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the sale, the chief executive officer now owns 597,915 shares in the company, valued at approximately $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 4.74% of the company’s stock.

Analysts Set New Price Targets

QURE has been the subject of several recent analyst reports. The Goldman Sachs Group lifted their price target on uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 12th. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of uniQure in a research report on Tuesday, December 10th. StockNews.com upgraded shares of uniQure to a “sell” rating in a research report on Wednesday, December 11th. Guggenheim reissued a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. Finally, Cantor Fitzgerald upped their price objective on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, uniQure has an average rating of “Moderate Buy” and a consensus target price of $32.13.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.